ROUGH QUARTER: Bristol-Myers Squibb Co. swings to a $711 million loss on a $1.8 billion charge for failed research and generic competition with decimated sales. It misses analysts' expectations and slashes its 2012 profit forecast.
THE NUMBERS: The loss equals 43 cents per share. Excluding charges Bristol made $969 million, or 56 cents per share. Generic competition to drugs including blood thinner Plavix, which had been the world's second-best-selling drug, cuts revenue 30 percent to $3.74 billion.
THE REACTION: One analyst says Bristol won't see much growth before 2020, and shares slide.